Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.

PURPOSE We evaluated dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging (DSC-MRI) using gadoteridol in comparison to the iron oxide nanoparticle blood pool agent, ferumoxytol, in patients with glioblastoma multiforme (GBM) who received standard radiochemotherapy (RCT). METHODS AND MATERIALS Fourteen patients with GBM received standard RCT and underwent 19 MRI sessions that included DSC-MRI acquisitions with gadoteridol on Day 1 and ferumoxytol on Day 2. Relative cerebral blood volume (rCBV) values were calculated from DSC data obtained from each contrast agent. T1-weighted acquisition post-gadoteridol administration was used to identify enhancing regions. RESULTS In seven MRI sessions of clinically presumptive active tumor, gadoteridol-DSC showed low rCBV in three and high rCBV in four, whereas ferumoxytol-DSC showed high rCBV in all seven sessions (p = 0.002). After RCT, seven MRI sessions showed increased gadoteridol contrast enhancement on T1-weighted scans coupled with low rCBV without significant differences between contrast agents (p = 0.9). Based on post-gadoteridol T1-weighted scans, DSC-MRI, and clinical presentation, four patterns of response to RCT were observed: regression, pseudoprogression, true progression, and mixed response. CONCLUSION We conclude that DSC-MRI with a blood pool agent such as ferumoxytol may provide a better monitor of tumor rCBV than DSC-MRI with gadoteridol. Lesions demonstrating increased enhancement on T1-weighted MRI coupled with low ferumoxytol rCBV are likely exhibiting pseudoprogression, whereas high rCBV with ferumoxytol is a better marker than gadoteridol for determining active tumor. These interesting pilot observations suggest that ferumoxytol may differentiate tumor progression from pseudoprogression and warrant further investigation.

[1]  Dieta Brandsma,et al.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.

[2]  J E Heiserman,et al.  Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements , 2009, American Journal of Neuroradiology.

[3]  Douglas C. Miller,et al.  Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.

[4]  A. Brandes,et al.  Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. , 2008, Neuro-oncology.

[5]  Yue Cao,et al.  Clinical investigation survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT , 2006 .

[6]  M Takahashi,et al.  Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. , 1998, AJR. American journal of roentgenology.

[7]  A Gregory Sorensen,et al.  Perfusion MR imaging: moving forward. , 2008, Radiology.

[8]  G. van Kaick,et al.  Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy , 2002, Neuroradiology.

[9]  J. Fike,et al.  The Radioresponse of the Central Nervous System: A Dynamic Process , 2000, Radiation research.

[10]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[11]  M. Pintilie,et al.  Hypoxia and Hypoxia-Inducible Factor-1 Target Genes in Central Nervous System Radiation Injury , 2004, Clinical Cancer Research.

[12]  G Johnson,et al.  Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. , 1999, Radiology.

[13]  Michael H Lev,et al.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. , 2004, AJNR. American journal of neuroradiology.

[14]  Ying Lu,et al.  Survival analysis in patients with glioblastoma multiforme: Predictive value of choline‐to‐n‐acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume , 2004, Journal of magnetic resonance imaging : JMRI.

[15]  M. Morino,et al.  Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery —In malignant glioma— , 2004, Annals of nuclear medicine.

[16]  W. Koch,et al.  Positron Emission Tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus Magnetic Resonance Imaging in the Diagnosis of Recurrent Gliomas , 2005, Neurosurgery.

[17]  A. Brandes,et al.  MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Yue Cao,et al.  Physiologic and metabolic magnetic resonance imaging in gliomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P Bachert,et al.  Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. , 2001, AJNR. American journal of neuroradiology.

[20]  Michael Jerosch-Herold,et al.  THE POTENTIAL OF FERUMOXYTOL NANOPARTICLE MAGNETIC RESONANCE IMAGING, PERFUSION, AND ANGIOGRAPHY IN CENTRAL NERVOUS SYSTEM MALIGNANCY: A PILOT STUDY , 2007, Neurosurgery.

[21]  Andrew E. Sloan,et al.  Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma , 2007, Journal of Neuro-Oncology.

[22]  R. Salem,et al.  Gastrointestinal Perforation Due to Bevacizumab in Colorectal Cancer , 2007, Annals of Surgical Oncology.

[23]  A. J. van der Kogel,et al.  Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. , 2004, Molecular interventions.

[24]  K. Schmainda,et al.  Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. , 2008, Radiology.

[25]  A. Waldman,et al.  Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? , 2008, Radiology.

[26]  Xin Li,et al.  Dynamic MRI Using Iron Oxide Nanoparticles to Assess Early Vascular Effects of Antiangiogenic versus Corticosteroid Treatment in a Glioma Model , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[27]  D. Knol,et al.  Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence , 2009, Journal of Neurology.

[28]  E F Halpern,et al.  Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. , 1994, Radiology.

[29]  M. Berger,et al.  Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2009, Radiology.

[30]  Bart Neyns,et al.  Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. , 2009, Surgical neurology.